Evolent Health (NYSE:EVH) Shares Down 4.6% - Here's Why

Key Points

• Evolent Health's shares dropped by 4.6% during trading, closing at $8.07 with a volume decline of 79% compared to the average session volume.
• Analysts have varied price targets for Evolent Health, with a consensus average target of $17.21, while some firms set targets as high as $20.00.
• The company reported negative earnings of ($0.10) per share, missing analysts' expectations and reflecting a 31.3% decrease in revenue year-over-year.

Evolent Health, Inc (NYSE:EVH - Get Free Report) shares traded down 4.6% on Wednesday . The company traded as low as $8.02 and last traded at $8.07. 566,691 shares traded hands during trading, a decline of 79% from the average session volume of 2,705,852 shares. The stock had previously closed at $8.46.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. JMP Securities restated a "market outperform" rating and set a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. BTIG Research restated a "buy" rating and set a $20.00 price target on shares of Evolent Health in a research report on Tuesday. Piper Sandler boosted their price target on shares of Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday, August 28th. Canaccord Genuity Group restated a "buy" rating and set a $16.00 price target on shares of Evolent Health in a research report on Tuesday, September 9th. Finally, Stephens reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Evolent Health in a research note on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Evolent Health presently has an average rating of "Buy" and an average price target of $17.21.

Evolent Health Stock Down 4.0%

The business's 50 day moving average price is $9.28 and its 200-day moving average price is $9.47. The firm has a market capitalization of $954.77 million, a PE ratio of -5.01 and a beta of 0.73. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The company had revenue of $444.33 million during the quarter, compared to analysts' expectations of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. Evolent Health's revenue was down 31.3% on a year-over-year basis. During the same period last year, the firm posted $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current year.

Institutional Investors Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. grew its holdings in shares of Evolent Health by 99.2% in the second quarter. Osaic Holdings Inc. now owns 11,119 shares of the technology company's stock valued at $125,000 after purchasing an additional 5,537 shares in the last quarter. State of Wyoming grew its holdings in shares of Evolent Health by 38.6% in the second quarter. State of Wyoming now owns 45,999 shares of the technology company's stock valued at $518,000 after purchasing an additional 12,812 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Evolent Health by 92.2% in the second quarter. Hudson Bay Capital Management LP now owns 760,211 shares of the technology company's stock valued at $8,560,000 after purchasing an additional 364,664 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Evolent Health in the second quarter valued at approximately $58,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Evolent Health by 313.8% in the second quarter. Tower Research Capital LLC TRC now owns 14,202 shares of the technology company's stock valued at $160,000 after purchasing an additional 10,770 shares in the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.